Circularization of Aptamer Nanomedicine Improves Nuclease Resistance, Targeted Recognition, and Transdermal Effect for Topical Psoriasis Therapy
Nano Letters · 2025
DOI: 10.1021/acs.nanolett.5c02063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Zhe Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai 201804, P. R. China. Hauptthemen laut MEDLINE: Psoriasis, Aptamers, Nucleotide, Metal Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Education Commission, National Science Fund for Distinguished Young Scholars.
Abstract (Originalsprache)
Inhibiting excessive hyperproliferation and inflammatory responses of keratinocytes are two primary tasks against psoriasis, which, however, have not been well integrated by the current available nanomedicines. Herein, we develop a nucleic acid nanomedicine through coassembly of circular aptamers and gold nanoclusters via electrostatic interactions for psoriasis therapy. After topical application, this nanomedicine bearing vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) aptamers crosses the stratum corneum and enters the deep layers of psoriatic site, from which it specifically inhibits VEGF-mediated keratinocyte proliferation and TNF-α-mediated inflammatory responses simultaneously. More importantly, the circular aptamers further promote the nuclease resistance, targeted recognition, and transdermal effect of the nanomedicine, as compared to their linear counterparts. These improved synergistic actions effectively prevent and cure psoriasis of mice induced by imiquimod. It is anticipated that this study provides a general strategy for targeted regulation of intricate pathological microenvironments beyond psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai 201804, P. R. China.
- Department of Gynaecology and Obstetrics, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institu…
- Key Laboratory of Advanced Civil Engineering Materials of Ministry of Education, School of Materials Science and Engineering, Tongji University, Shanghai 201804, P. R. China.
- School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China.
ORCID-Profile: Zhe Liu, Yao Xu, Yuyan Qian, Yu Fan, Zhen Fan, Jianzhong Du, Yong Hu
Förderung
- National Key Research and Development Program of China
- Shanghai Municipal Education Commission
- National Science Fund for Distinguished Young Scholars
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Excellent Young Scientists Fund
- Interdisciplinary Project in ?Medicine + X? of Tongji University
Zitieren
APA
Liu, Z., Xu, Y., Qian, Y., Fan, Y., Fan, Z., Du, J., & Hu, Y. (2025). Circularization of Aptamer Nanomedicine Improves Nuclease Resistance, Targeted Recognition, and Transdermal Effect for Topical Psoriasis Therapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c02063
Vancouver
Liu Z, Xu Y, Qian Y, Fan Y, Fan Z, Du J, et al. Circularization of Aptamer Nanomedicine Improves Nuclease Resistance, Targeted Recognition, and Transdermal Effect for Topical Psoriasis Therapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c02063
BibTeX
@article{Liu2025,
author = {Liu, Zhe and Xu, Yao and Qian, Yuyan and Fan, Yu and Fan, Zhen and Du, Jianzhong and Hu, Yong},
title = {Circularization of Aptamer Nanomedicine Improves Nuclease Resistance, Targeted Recognition, and Transdermal Effect for Topical Psoriasis Therapy},
journal = {Nano Letters},
year = {2025},
doi = {10.1021/acs.nanolett.5c02063}
}
EUVIMED